Mayo’s medical might combining with Hilton’s eminent hospitality

Destination healthcare consumers and their traveling companions will soon enjoy all the niceties Hilton hotels have to offer—as long as the provider organization of the patient’s choice is the Mayo Clinic in Florida.

Mayo Clinic announced the $70 million project Sept. 28, stating construction is to begin next summer and finish in early 2024.

Mayo’s partners in the venture are the hotel developer Concord Hospitality Enterprises and the real estate private equity firm Whitman Peterson, according to the announcement.  

“As a premier destination medical center, exceeding the current and future needs of our patients is our top priority,” says Kent Thielen, MD, Mayo Clinic Florida’s CEO. “We are excited to be offering this type of high-end hotel accommodation to further enhance our patients’ experience when traveling to our campus for care.”

Hilton CEO Chris Nassetta adds that the combination medical campus/vacation complex will allow the company to “offer patients and their families our signature hospitality when they stay with us while receiving world-class care.”

Full announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.